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Background. Congenital nephrotic syndrome (CNS) causes
significant renal failure, and is classified into two types: (1)
Finnish type; and (2) other, including diffuse mesangial scle-
rosis. Mutations of NPHS1 and NPHS2, which encode the
slit diaphragm components nephrin and podocin, cause CNS
and autosomal-recessive familial steroid-resistant nephrotic
syndrome, respectively. Most patients with Finnish-type CNS
in Europe and the United States have NPHS1 mutations.
However, NPHS2 mutations have been detected in some
cases. Mutations in ACTN4, encoding a-actinin-4, cause an
autosomal-dominant focal segmental glomerulosclerosis. a-
actinin-4 stabilizes the podocyte cytoskeleton structure, con-
necting with actin filaments. WT1 mutations, causing Wilm’s
tumor, have been demonstrated in some CNS patients with dif-
fuse mesangial sclerosis. Systematic investigation of genes for
CNS in Japan has never been performed.
Methods. To clarify the role of mutations in these four genes,
we used polymerase chain reaction (PCR) and direct sequenc-
ing to investigate all exons and exon-intron boundaries for these
genes in 13 unrelated CNS patients from regional pediatric kid-
ney disease centers in Japan.
Results. A novel homozygous nonsense mutation of NPHS1,
E246X in exon 7, and a novel homozygous deletion mutation
of NPHS1, 2156 2163del in exon 16 were detected in one pa-
tient each. A novel homozygous nonsense mutation of NPHS2,
R196X in exon 5, was found in one patient, and the same
heterozygous nonsense mutation was detected in another. No
ACTN4 or WT1 mutations were detected.
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Conclusion. These studies demonstrate that mutation of
NPHS1 is not a major cause of CNS in Japanese patients, and
that mutation of NPHS2 can be responsible for CNS in this
population.
Congenital nephrotic syndrome (CNS) is defined as
nephrotic syndrome occurring before 3 months of age
[1]. CNS is a cause of end-stage renal disease (ESRD),
and is characterized by massive proteinuria and nephrotic
syndrome soon after birth. CNS can be classified into two
types: (1) Finnish type (CNF); and (2) other, including dif-
fuse mesangial sclerosis (DMS) [1]. CNF, the most com-
mon type of CNS, is an autosomal-recessive disorder and
is geographically widespread. The incidence of CNF is
more often in Finland, but is considerably lower in other
countries [2]. The main diagnostic criteria of CNF are
massive proteinuria, often starting in utero, a large pla-
centa, and onset of nephritic syndrome soon after birth
(before the age of 1 month). Patients with CNF usu-
ally show normal glomerular filtration rate (GFR) during
the first 6 months. Characteristic renal histopathologic
changes are diffuse mesangial proliferation and micro-
cystic dilatation of the proximal tubules [1].
In 1998, NPHS1 was identified as the causative gene of
CNF and was shown to encode a putative transmembrane
protein termed nephrin that belongs to the immunoglob-
ulin superfamily [2]. Nephrin is expressed exclusively at
the slit diaphragm joining the podocyte foot processes
and is an important component of the slit diaphragm
[3]. It plays a crucial role in the selective filtration func-
tion of the slit diaphragm, because massive proteinuria
is a consequence of nephrin absence or malfunction [4].
Over 60 different NPHS1 mutations have been detected
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in Finnish, European, North African, Indian, and North
American patients, including deletions, insertions, non-
sense, missense, splice site, and promoter mutations [2,
4–7]. The typical Finnish mutations, a 2 bp deletion in
exon 2 (Fin-major) and a nonsense mutation in exon 26
(Fin-minor), are rare in other populations.
In 2000, the NPHS2 gene was identified as the causative
gene of autosomal-recessive familial steroid-resistant
nephrotic syndrome [8]. The gene product, podocin, is
an integral membrane protein that is localized to the
podocyte foot process membrane at the insertion site
of the slit diaphragm [9]. It interacts with nephrin via
its C-terminus and may increase nephrin-induced stim-
ulation of mitogen-activated protein kinase (MAPK) [9,
10]. It may serve in the structural organization of the slit
diaphragm and the regulation of its filtration function.
Koziell et al [11] reported that two of five patients with se-
vere CNF in whom NPHS1 mutations were not detected
had NPHS2 mutations.
Mutations in the ACTN4 gene, encoding a-actinin-4,
have been demonstrated in an autosomal-dominant
form of focal segmental glomerulosclerosis (FSGS) [12].
a-actinin-4 is a novel member of the actin family of actin-
filament cross-linking proteins. It is expressed signifi-
cantly in the glomerular podocyte and has an important
function in podocytes. Furthermore, it is up-regulated
during the evolution of nephrotic syndrome in animal
models [13]. To date, no ACTN4 mutation has been re-
ported in CNS patients.
WT1 is a zinc finger transcription factor involved in
renal and gonadal development and in Wilm’s tumor
[14]. Constitutional WT1 gene mutations have been de-
scribed in most patients with Denys-Drash syndrome
(DDS) [15]. This syndrome includes DMS, male pseudo-
hermaphroditism, and/or Wilm’s tumor. Isolated DMS
(IDMS) is an early-onset nephropathy and most often
progresses to end-stage renal failure by 3 years of age.
This nephropathy can occur in the absence of other ab-
normalities and there is no histologic difference between
this form and DDS [16]. IDMS is an important cause of
CNS and infant nephrotic syndrome. Jeanpierre et al [17]
reported that four of ten IDMS patients had WT1 het-
erozygous mutations. Recently, Ruf et al [18] reported
the novel heterozygous missense mutation of WT1 in a
CNS patient.
Although CNS can usually be diagnosed and classified
by clinical manifestations, some uncertainties remain. It is
now possible to diagnose CNF by analysis of the NPHS1
gene. In the future, classification of CNS will be mod-
ified by the results of gene analysis. Knowledge of the
causative gene mutations in Japanese children with CNS
is therefore important, but systematic investigation has
never been performed. In this study, to clarify the role of
these gene mutations, all exons and exon-intron bound-
aries for all four genes were analyzed in 13 Japanese CNS
patients from 13 unrelated families.
METHODS
Patients
All methods were reviewed and approved by the ethics
committees of Wakayama Medical University Hospi-
tal. A total of 13 Japanese CNS patients from 13 unre-
lated families (three male and ten female patients) were
studied after informed consent had been obtained. The
patients were followed up at five regional centers for pedi-
atric kidney disease in Japan: Surugadai Nihon University
Hospital, Chiyoda; Tokyo Metropolitan Kiyose Chil-
dren’s Hospital, Kiyose; Shizuoka Children’s Hospital,
Shizuoka; Osaka Medical Center and Research Institute
for Maternal and Child Health, Osaka; and Kyushu Kosei
Nenkin Hospital, Kitakyushu. All patients had the typi-
cal clinical finding of onset of proteinuria and nephrotic
syndrome between birth and 1 month of age, with a clin-
ical course to ESRD at later than the first 6 months of
life (except patients 2 and 5). In addition, the patients
in this study were clinically evaluated on the basis of the
following criteria: prematurity, a large placenta (placen-
tal weight >25% of infant birth weight) and, whenever
possible, renal histology compatible with CNF. Table 1
shows the results of this evaluation. All cases were spo-
radic. Renal histologic examination was available in ten
of the 13 patients. Nine of these ten patients showed typ-
ical histologic findings of CNF (microcystic dilatation of
the tubules and diffuse mesangial proliferation) [1] and
one (patient 6) showed only mild mesangial proliferation.
CNS patients with DMS and all secondary CNS patients
were excluded from the study.
DNA sequencing
Genomic DNA was extracted and purified from pe-
ripheral leukocytes in whole-blood samples by using a
DNA isolation kit (Takara, Ohtsu, Japan). Individual ex-
ons of NPHS1, NPHS2, ATCN4, and WT1 were ampli-
fied by polymerase chain reaction (PCR). The primers for
NPHS1, NPHS2, and WT1 were designed on the basis of
previously published information regarding intron-exon
boundaries [5, 8, 17]. All primers for ATCN4 were de-
signed from intronic sequences (Table 2). The PCR prod-
ucts were purified with a QIA Quick PCR Purification
Kit (Qiagen, Hilden, Germany). The purified product
was cycle-sequenced with Big-Dye terminators (Applied
Biosystems, Foster City, CA, USA), and the cycle se-
quence product was analyzed with an automated se-
quencer (ABI Prism 310 Genetic Analyzer) (Applied
Biosystems).
RESULTS
NPHS1 analysis
A novel homozygous nonsense mutation of NPHS1,
E246X (736G>T in exon 7), was detected in patient 1
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Table 1. Criteria matching and mutations in patients with congenital nephrotic syndrome
Age at Typical renal
Placenta diagnosis of Age at histologic findings of
weight (>25% of nephrotic end-stage renal congential nephrotic
Patient Prematurity birth weight) syndrome disease (>6 months) syndrome (Finnish) Mutation
1 No Yes 1 month Yes (1 year 6 months) Yes NPHS1; E246X (homozygous)
2 Yes Yes 1 month Not yet at 4 months Not available NPHS1; 2156 2163del (homozygous)
3 Yes Yes At birth Yes (10 months) Yes NPHS1; R460Q (heterozygous)
4 No Yes 1 month Yes (2 years 2 months) Not available NPHS1; D105N (heterozygous)
5 Yes No 1 month No (1 month) Not available NPHS2; R196X (homozygous)
6 Yes Unknown 1 week Yes (5 years 3 months) No NPHS2; R196X (heterozygous)
7 Yes Yes 2 weeks Yes (2 years 1 month) Yes
8 Yes Yes At birth Yes (9 months) Yes
9 No Yes 1 week Yes (1 year 4 months) Yes
10 Yes Yes At birth Yes (3 years 8 months) Yes
11 Yes Yes At birth Yes (2 years 1 month) Yes
12 Yes Yes 2 weeks Yes (4 years 2 months) Yes
13 Yes Yes At birth Yes (9 months) Yes
Table 2. ACTN4 primer sequencesa
Annealing
Exon Sense (5′-3′) Antisense (5′-3′) Size (bp) temperature (◦C)
1 GGCCTGCCCTTATGAATCATTC TCTAGCTCGGCGATTCCTCC 221 53
2 TGCAGGTGTGTGGAGAGAGC TGCAGCTATTAAGGGGTGCC 115 62
3 GCCCTCTCTCCCTTTCTCTC AAGCGCCCTGCCACCAACAA 120 64
4 GGGTGGTTTGGAGCCTTTCT TTCAGCTCTCCTCTAACCCG 87 64
5 CCTGAGCCGAAAGTCCCATC AACAGGGCAGGTGGGAGGAA 88 64
6 GCCCCAGAGGTCATGCTTGC GCACAAGGCTCTCCCAGGCT 79 64
7 GAAGAAACCCCCAACCCTCG CCCAAAGCTCTGATGTGCCC 82 64
8 GATCCCAGTGAGTGACGCCT GCAAGAGAAATGAGGTGAGC 86 64
9 CCTCTCCTTCCCCTCTGTGA CTCGCTGCCACACCTGCTTT 93 60
10 GCAGGAATCGTGGAGAAGTT TAGGAAAGATTACGCTGGCC 231 60
11 CACCTTCCCATCAGCATCCC TGAGAGACAGGAGGGGAGCA 148 64
12 TCTCTTTCCCTCCCTCTGCT GGTGAGAGCCAGGTGATGAT 151 62
13 TGGTTATCACCTGTTAACCAGC AGGGAAGGCAGGTCAGTATG 109 60
14 CACCCCTCCTGCTCACATAC TTGGGAAGATGGGGGGCCGG 141 64
15 TCGAGGAGATTGAGGTTCGC CATGGTCCCGTTTTGGCACC 183 62
16 CCCCGCAAATCATCAACTCC TGGGTGGTGAGAATTGGGAC 135 60
17 AGTTGTGAGCAGTGGGCCTT AACAACAGACAGCAGACAGC 180 60
18 GCGGGAGGACAGTTCACAGT TGTGGGCTGGTACGGCAACG 147 64
19 TTTCCCTCCCCTACGTGTCC GATGGCACACAGGATGGCAG 81 60
20 CTCTCTCGGCTGTTTCCCTG TCTCGCTCACCTTGTCCCCT 159 60
21 CAGTGTGTGGGTGGGGATGG TGCATAGATACAGAGTGGAG 159 58
aPrimer sequences are based on the human ACTN4 genomic sequence (accession no. NT011109).
(Table 1) (Fig. 1A). This nucleotide change directly in-
troduces a stop codon (TAG), leading to a truncated pro-
tein. Patient 1 was a 12-year-old Japanese boy with no
family history of renal disease. At birth, a large placenta
had been recorded and at the age of 1 month he was di-
agnosed as having nephrotic syndrome. His condition de-
teriorated to ESRD at 18 months of age, and continuous
ambulatory peritoneal dialysis was begun. He received a
renal transplant when he was 8 years old, after a bilateral
nephrectomy. The parents were not consanguineous. The
mother of the patient was healthy, although the same het-
erozygous mutation was identified in her. Gene analysis
of the father was not available.
A novel homozygous deletion mutation of NPHS1,
2156 2163del in exon 16, was detected in patient 2
(Table 1) (Fig. 1B). This mutation leads to a frame shift
and a truncated protein. Patient 2 was a 4-month-old
Japanese girl and the child of healthy consanguineous
parents between cousins. She was born at 36 gestational
weeks and weighed 2718 g at birth. A large placenta
(1250 g) had been recorded at birth. At 1 month of age
she was diagnosed as having nephrotic syndrome. She
showed a normal serum creatinine level at 4 months of
age. Gene analysis of the parents was not available.
Two heterozygous missense mutations of NPHS1,
R460Q (1379G>A in exon 11) (Table 1) (Fig. 1C) and
D105N (novel mutation, 313G>A in exon 3) (Table 1)
(Fig. 1D), were detected in patients 3 and 4, respectively.
Patient 3 was a Japanese boy with no family history of re-
nal disease. At birth a large placenta had been recorded
and he was diagnosed as having nephrotic syndrome. His
condition deteriorated to ESRD at 10 months of age. The
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C G AG T
Normal
A
C G A T G
Normal
D
C C GA A
Normal
E F
Normal
GC T GCA C T GC CA G A A C T C T G A G GG
B
Normal
C C G G G
C
C T AG T
Patient 1
E246X
homozygote
C N A T G
Patient 4
D105N
heterozygote
C T G A A
Patient 5
R196X
homozygote
C N G A A
Patient 6
R196X
heterozygote
G C CA G A AC T C T G AG GG
Patient 2
2156_2163del
homozygote
C C N G G
Patient 3
R460Q
heterozygote
Fig. 1. Detection of NPHS1 and NPHS2 mutations by direct sequencing. (A) A novel nonsense mutation of NPHS1, E246X (736G>T in exon 7),
in patient 1. (B) A novel homozygous deletion mutation of NPHS1, 2156 2163del, in exon 16 in patient 2. (C) A heterozygous missense mutation
of NPHS1, R460Q (1379G>A in exon 11), in patient 3. (D) A novel heterozygous missense mutation of NPHS1, D105N (313G>A in exon 3), in
patient 4. (E) A novel homozygous nonsense mutation of NPHS2, R196X (586C>T in exon5), in patient 5. (F) The R196X nonsense mutation of
NPHS2 found in patient 5 is heterozygous in patient 6.
parents were not consanguineous. The mother of patient
3 was healthy, although the same heterozygous mutation
was identified in her. This mutation was not observed in
the father of patient 3. Patient 4 was a Japanese boy with
no family history of renal disease. At the age of 1 month
he was diagnosed as having nephrotic syndrome. His con-
dition deteriorated to ESRD at 26 months of age. The
parents were not consanguineous. Informed consent was
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not given for gene analysis of the parents of patient 4.
To rule out polymorphisms, 200 chromosomes of healthy
Japanese control individuals were checked for mutations.
Both mutations were absent in 200 chromosomes of them.
Three single-nucleotide polymorphisms (349G>A in
exon 3, 2289C>A in exon 17, and 3315G>A in exon 26)
in the coding region were observed in nine, four, and two
patients, respectively. The typical Finnish mutations were
not detected in any of the 13 patients.
NPHS2 analysis
A novel homozygous nonsense mutation of NPHS2,
R196X (586C>T in exon 5), was detected in patient
5 (Table 1) (Fig. 1E). The same heterozygous muta-
tion was also identified in patient 6 (Table 1) (Fig. 1F).
This nucleotide change directly introduces a stop codon
(TGA), leading to a truncated protein. Patient 5 was a
Japanese girl. She was diagnosed at birth as having Eb-
stein anomaly and adrenogenital syndrome. Proteinuria
was detected at birth and at 1 month of age she was di-
agnosed as having nephrotic syndrome and ESRD. The
patient died of infection and heart and renal failure at
3 months of age. This patient had not shown a giant pla-
centa at birth. Her parents and three siblings were healthy
and did not demonstrate renal disease. One sibling had
adrenogenital syndrome. The etiology of the patient’s or
sibling’s adrenogenital syndrome was unknown. The par-
ents were not consanguineous. Informed consent was not
obtained for gene analysis of her family members. Pa-
tient 6 was a Japanese girl who was diagnosed as having
nephrotic syndrome at 1 week of age. Information about
possible giant placenta at birth was not available. Her par-
ents were healthy and would not give informed consent
for gene analysis.
Three single-nucleotide polymorphisms (102G>A in
exon 1, 954T>C in exon 8, and 1038A>G in exon 8) in
the coding region were also observed in one, one, and
seven patients, respectively.
ACTN4 analysis
No ACTN4 mutation was detected in any of the 13 CNS
patients. One single-nucleotide polymorphism (605C>T
in exon 5) in the coding region of the ACTN4 gene was
observed in nine patients.
WT1 analysis
No WT1 mutation was detected in any of the 13 CNS
patients.
DISCUSSION
In this type of study, the stringency of patient criteria
matching is important, and we were careful in selecting
patients for the analysis. Although there is no specific
feature that identifies CNF, we assessed the phenotype
of our patients by evaluating several characteristics that
favor the diagnosis of CNF, such as prematurity, large
placenta, and renal histologic changes. Our patients form
a clinically homogeneous group (Table 1) and we could
not detect any apparent difference between patients 1 and
2 (NPHS1 homozygous mutations detected) and patients
7 to 13 (no mutation detected). Therefore, an important
finding in our study is that clinically homogenous CNS
patients have genetic heterogeneity.
Two novel homozygous mutations of NPHS1, E246X
and 2156 2163del, were detected in two of the 13 Japanese
patients with CNS (patient 1 and patient 2, respectively).
These mutations are located in the extracellular part of
the nephrin protein containing the Ig-like module. The
putative truncated proteins would lack the intracellu-
lar and transmembrane domains, but only limited infor-
mation is available on the active domains of nephrin.
Huber, Kottgen, and Shilling [10] have recently demon-
strated that nephrin is a signaling molecule that stimulates
MAPK, and that podocin, which binds to the intracellu-
lar domain of nephrin, enhances nephrin-induced signal-
ing. Therefore, it was deduced that these are causative
mutations.
Two heterozygous missense mutations of NPHS1,
R460Q (1379G>A in exon 11) and D105N (novel muta-
tion, 313G>A in exon 3), were detected in patients 3 and
4, respectively. Since CNF is a recessive disorder, it is un-
likely that these mutations alone cause disease. In fact, the
mother of patient 3 was healthy despite carrying the same
heterozygous mutation, although a homozygous R460Q
mutation has already been reported in a CNF patient [6].
The missense mutation D105N is located in the Ig-like
module one and affects an amino acid conserved in mice.
The asparagine (N)-for-aspartate (D) substitution lacks
the negative charge of a carboxylate group [19]. Charge
neutralization may have an influence on the function of
nephrin. Lenkkeri et al [5] reported mutations in only one
allele of NPHS1 in five of 79 patients with CNF. It is not
clear whether these mutations affect nephrin function.
We checked 200 chromosomes of healthy Japanese con-
trol individuals for mutations to rule out polymorphisms.
Both mutations were absent in 200 chromosomes of them.
Therefore, although it is thought that at least both mu-
tations are not popular polymorphisms, whether these
amino acid changes are rare polymorphisms or whether
they cause disease will not be resolved until a functional
assay is performed.
Over 60 different NPHS1 mutations have been de-
tected to date, including deletions, insertions, nonsense,
missense, splice site, and promoter mutations [2, 4–7].
NPHS1 mutations are distributed throughout the gene,
emphasizing a functional requirement for both extracel-
lular and intracellular domains. To date, all NPHS1 mu-
tations resulted in a consistently severe CNF phenotype,
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regardless of location or predicted effect on the protein
except for the homozygous R1160X mutation, which was
associated with mild CNF disease in approximately 50%
of cases, the majority female [1, 11]. Missense mutations
are all located within the extracellular part and cluster to
exons coding for the Ig-like motifs two, four, and seven [1,
5, 6, 11]. With our findings, E246X (homozygous) in pa-
tient 1, 2156 2163del (homozygous) in patient 2, R460Q
(heterozygous) in patient 3 and D105N (heterozygous) in
patient 4 are located between Ig-like motifs one and two,
between Ig-like motifs six and seven, and in Ig-like motif
four and in Ig-like motif one, respectively. These findings
are consistent with previous reports. It is difficult to state
the genotype/phenotype correlations in our patients. All
patients we examined showed clinically severe CNS. Aya,
Tanaka, and Seino [20] described a Japanese severe CNF
patient homozygous for D819V missense mutation. The
typical Finnish mutations are rare in non-Finnish popu-
lations [5]. Koziell et al [11] reported that 23 different
NPHS1 mutations were detected in 29 of 37 CNS pa-
tients from England, India, Malta, Pakistan, and Turkey.
They suggested that, because of ethnic diversity of the
test populations, the wide variety of different mutations
detected in non-Finnish patients was likely to be the re-
sult of de novo events. An Italian study of 15 patients with
CNS from 13 unrelated families revealed that all had ho-
mozygous NPHS1 mutations but that the typical Finnish
mutations were not detected, suggesting that each CNS
family may have its own mutation [7]. In the current study,
a clearly causative mutation of NPHS1 was found in only
two of the 13 patients. Although it is possible that a few
mutations yet to be identified in our patients are located
in regulatory elements of NPHS1, the rate of detection of
NPHS1 mutation in this study is obviously low. This is an
important finding of the study. CNS is a very rare disease
in Japan. The 1998 report of the Japanese National Reg-
istry data showed that the number of new patients with
CNS was four, and that the total number of pediatric pa-
tients with CNS was 34 [21]. Therefore, the patients we
studied represented a considerable fraction of the total
number of Japanese CNS children alive during the time
period. The study demonstrates that NPHS1 mutation
does not appear to be an exclusive or major cause of CNS
in Japanese children. The reason for the low incidence of
NPHS1 mutations is uncertain, but racial factors may be
involved.
One novel nonsense mutation of NPHS2, R196X, was
detected in patient 5 (homozygous mutation) and patient
6 (heterozygous mutation). This nucleotide change di-
rectly introduces a stop codon (TGA), presumably result-
ing in a message for a truncated protein. This mutation is
located in the intracellular part of the carboxy-terminal
domain of podocin. Recent data suggest that podocin
binds to CD2-associated protein, CD2AP, a cytoplasmic
binding partner of nephrin, and nephrin via its carboxy-
terminal domain, in vitro and in vivo, and might serve in
the structural organization of the slit diaphragm and regu-
lation of its filtration function [9]. Therefore, we speculate
that R196X (586C>T) is a causative mutation in patient 5.
Patient 6 was heterozygous for the same nonsense muta-
tion of NPHS2. To our knowledge, this is the first report of
a heterozygous nonsense mutation of NPHS2 in a patient
with CNS, although heterozygous mutations of NPHS2
have previously been reported in patients with steroid-
resistant nephrotic syndrome [22]. It is not clear whether
this heterozygous mutation participates in disease. Since
NPHS2 is responsible for autosomal-recessive familial
steroid-resistant nephrotic syndrome, it is likely that this
patient has a second mutation elsewhere in the promoter
or intron areas of NPHS2.
Koziell et al [11] reported that two of five patients with
typically severe CNF in whom NPHS1 mutations were
not detected had homozygous NPHS2 mutations. They
also emphasized the importance of screening for both
NPHS1 and NPHS2 mutations in CNS, especially when
the NPHS1 mutation is not detected. Recently, Caridi
et al [23] described an infantile variant of nephritic syn-
drome that arose within 6 months of life associated with
double homozygous mutations of NPHS2. Our studies
demonstrate for the first time that NPHS2 mutation can
be responsible for CNS in Japanese patients, although it
is not a major cause of CNS, and support the importance
of screening for both NPHS1 and NPHS2 mutations in
patients with CNS.
NPHS2 mutations were first detected in familial
autosomal-recessive steroid-resistant nephrotic syn-
drome [8]. Thereafter, NPHS2 mutations were also iden-
tified in sporadic cases of steroid-resistant nephrotic
syndrome [22, 24, 25], late-onset FSGS [26]. To date, a
wide range of phenotypic variability between individuals
with the same genotype was revealed [27, 28]. Weber et
al [28] reported that the mutation detection rate was 43%
for familial autosomal-recessive and 10.5% for sporadic
steroid-resistant nephrotic syndrome. Karle et al [22] also
reported that 46% of familial FSGS patients were caused
by NPHS2 mutations, and these mutations were also seen
in 28% of sporadic FSGS cases. NPHS2 mutations were
found in patients of Italian, French, German, and Israeli-
Arab origin, but Israeli-Jewish origin and Japanese chil-
dren were found not to carry the mutations [22, 24, 25,
27, 29]. The interethnic differences may play a role in
the incidence of these mutations. Although NPHS2 mu-
tations are distributed throughout the entire gene, a large
majority of mutations were located in exons 4, 5, and 7,
encoding the C-terminal part of podocin. NPHS2 muta-
tions cluster in the early C-terminal cytoplasmic domain,
the region conserved among members of the stomatin
protein family [28]. Our findings R196X in exon 5 of pa-
tients 5 and 6 are consistent with previous reports. With
the genotype/phenotype correlations, Weber et al [28]
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reported that patients with frame shift or nonsense mu-
tations in the homozygous or compound heterozygous
state had an early mean age of onset, as was the case
with homozygous R138Q mutations. With our findings,
although both patient 5 (R196X homozygous) and pa-
tient 6 (R196X heterozygous) showed CNS, there was
considerable difference with age at ESRD between pa-
tients 5 and 6 (1 month and 63 months). The state of
homozygous or heterozygous in NPHS2 mutations may
affect clinical severity.
The 13 patients in this study were also screened for
ACTN4 and WT1 mutations, but no causative ACTN4
and WT1 mutations were detected. This suggests that
ACTN4 and WT1 mutations are not a major cause of
CNS in Japanese children.
The fact that NPHS2 mutations lead to both FSGS ap-
pearing later in life and CNS [8, 11] suggests the possi-
bility that gene mutations of proteins which interact with
nephrin such as a-actinin-4 may also lead to CNS. At
present, in CNS patients without DMS or FSGS, there is
no proven evidence supporting screening for ACTN4 and
WT1 mutations. However, considering the critical impor-
tance of an intact submembranous actin skeleton in the
podocyte [12, 30] and the fact that we did not find muta-
tions in NPHS1 and NPHS2 in a considerable fraction
of our CNS patients, we were encouraged to perform
ACTN4 screening in CNS patients. Recently, the novel
heterozygous missense mutation of WT1 in a CNS patient
has been reported, although her renal histologic profile
was not reported [18].
CONCLUSION
The results of this study show that the incidence of
NPHS1 mutation in Japanese patients with CNS is low,
demonstrating that NPHS1 mutation is not an exclusive
or major cause of CNS in Japanese children. The study
also demonstrates a racial difference in the incidence
of NPHS1 mutation. In addition, NPHS2 mutation can
also be responsible for CNS in Japanese children. It is
important, therefore, that molecular diagnosis of CNS
in Japanese patients should include mutational analy-
sis of both the NPHS1 and NPHS2 genes. Gene mu-
tations of other podocyte-specific proteins that interact
with nephrin and podocin, such as CD2AP, a cytoplas-
mic binding partner of nephrin, or Neph1, may also be
responsible for CNS in Japanese patients.
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